Spermidine Tested in Elderly Heart Disease Patients in Phase 2 Trial
A completed Phase 2 RCT examines whether spermidine supplementation benefits elderly patients with coronary artery disease.
Summary
Researchers at the University of Aarhus conducted a randomized, double-blind, placebo-controlled Phase 2 trial testing spermidine — a naturally occurring polyamine linked to autophagy induction and cellular longevity — in elderly patients with coronary artery disease (CAD), including those with prior myocardial infarction. Spermidine has attracted significant interest in aging science because it mimics some effects of caloric restriction by activating autophagy, the cellular recycling process that declines with age and contributes to cardiovascular disease progression. This trial represents one of the first controlled human studies to evaluate spermidine specifically in an older, high-cardiovascular-risk population. The trial is now completed, making its eventual full results highly anticipated by both longevity researchers and cardiologists looking for evidence-based supplement strategies.
Detailed Summary
Spermidine, a polyamine found naturally in foods like wheat germ, aged cheese, and mushrooms, has emerged as one of the most promising longevity-associated compounds in recent years. It acts primarily by inducing autophagy — the cellular housekeeping process that clears damaged proteins and organelles — a mechanism that declines with age and is implicated in cardiovascular aging, atherosclerosis, and heart failure. Preclinical evidence and early observational studies have suggested that higher spermidine intake correlates with reduced cardiovascular mortality and better cardiac function in aging populations.
This Phase 2 trial, registered as NCT06186102 and sponsored by the University of Aarhus, directly tests spermidine supplementation against placebo in elderly patients carrying an established diagnosis of coronary artery disease, including those with prior myocardial infarction. The two-armed, parallel-group, randomized, double-blind, single-centre design represents a rigorous methodological approach appropriate for this stage of clinical investigation. The trial is listed as completed as of 2024.
The study population — elderly CAD patients — is particularly meaningful. This group experiences accelerated cardiovascular aging, impaired autophagy, and elevated chronic inflammation, making them theoretically ideal candidates to benefit from spermidine's mechanisms. Demonstrating efficacy here would have direct translational value for a large and vulnerable segment of the aging population.
While the full results have not yet been published in peer-reviewed form, the completion of this trial is an important milestone. Outcomes likely include cardiac function measures, inflammatory biomarkers, and safety endpoints. Positive results would substantially strengthen the case for spermidine as a cardioprotective longevity intervention.
Caveats include the single-centre design, which limits generalizability, and the absence of published data at this time. The dosing regimen, duration of treatment, and specific outcome measures remain unreported, making it impossible to fully evaluate the trial's scope or statistical power from publicly available information.
Key Findings
- Phase 2 RCT of spermidine vs. placebo in elderly coronary artery disease patients is now completed.
- Spermidine induces autophagy, a cellular recycling process that declines with age and drives cardiovascular disease.
- Target population includes elderly patients with ischemic heart disease and prior myocardial infarction.
- Rigorous double-blind, randomized, placebo-controlled design strengthens potential evidence quality.
- Results, once published, could support spermidine as an evidence-based cardioprotective supplement in older adults.
Methodology
Randomized, double-blind, placebo-controlled, two-armed parallel-group Phase 2 clinical trial conducted at a single centre (University of Aarhus). Participants were elderly patients diagnosed with ischemic heart disease or myocardial infarction. The trial status is listed as completed as of 2024.
Study Limitations
Only the trial registration abstract is available; no outcome data, dosing details, trial duration, or specific endpoints have been published, so the clinical impact cannot yet be assessed. The single-centre design may limit generalizability across diverse populations. Summary is based on the abstract and trial registry entry only.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: